Skip to main content

Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.

Publication ,  Journal Article
Hall, G; Rowell, J; Farinelli, F; Gbadegesin, RA; Lavin, P; Wu, G; Homstad, A; Malone, A; Lindsey, T; Jiang, R; Spurney, R; Tomaselli, GF ...
Published in: Am J Physiol Renal Physiol
June 15, 2014

The emerging role of the transient receptor potential cation channel isotype 6 (TRPC6) as a central contributor to various pathological processes affecting podocytes has generated interest in the development of therapeutics to modulate its function. Recent insights into the regulation of TRPC6 have revealed PKG as a potent negative modulator of TRPC6 conductance and associated signaling via its phosphorylation at two highly conserved amino acid residues: Thr(69)/Thr(70) (Thr(69) in mice and Thr(70) in humans) and Ser(321)/Ser(322) (Ser(321) in mice and Ser(322) in humans). Here, we tested the role of PKG in modulating TRPC6-dependent responses in primary and conditionally immortalized mouse podocytes. TRPC6 was phosphorylated at Thr(69) in nonstimulated podocytes, but this declined upon ANG II stimulation or overexpression of constitutively active calcineurin phosphatase. ANG II induced podocyte motility in an in vitro wound assay, and this was reduced 30-60% in cells overexpressing a phosphomimetic mutant TRPC6 (TRPC6T70E/S322E) or activated PKG (P < 0.05). Pretreatment of podocytes with the PKG agonists S-nitroso-N-acetyl-dl-penicillamine (nitric oxide donor), 8-bromo-cGMP, Bay 41-2772 (soluble guanylate cyclase activator), or phosphodiesterase 5 (PDE5) inhibitor 4-{[3',4'-(methylenedioxy)benzyl]amino}[7]-6-methoxyquinazoline attenuated ANG II-induced Thr(69) dephosphorylation and also inhibited TRPC6-dependent podocyte motility by 30-60%. These data reveal that PKG activation strategies, including PDE5 inhibition, ameliorate ANG II-induced podocyte dysmotility by targeting TRPC6 in podocytes, highlighting the potential therapeutic utility of these approaches to treat hyperactive TRPC6-dependent glomerular disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Physiol Renal Physiol

DOI

EISSN

1522-1466

Publication Date

June 15, 2014

Volume

306

Issue

12

Start / End Page

F1442 / F1450

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • TRPC6 Cation Channel
  • TRPC Cation Channels
  • Signal Transduction
  • Podocytes
  • Phosphorylation
  • Phosphoric Monoester Hydrolases
  • Phosphodiesterase 5 Inhibitors
  • NFATC Transcription Factors
  • Models, Animal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hall, G., Rowell, J., Farinelli, F., Gbadegesin, R. A., Lavin, P., Wu, G., … Winn, M. P. (2014). Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. Am J Physiol Renal Physiol, 306(12), F1442–F1450. https://doi.org/10.1152/ajprenal.00212.2013
Hall, Gentzon, Janelle Rowell, Federica Farinelli, Rasheed A. Gbadegesin, Peter Lavin, Guanghong Wu, Alison Homstad, et al. “Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.Am J Physiol Renal Physiol 306, no. 12 (June 15, 2014): F1442–50. https://doi.org/10.1152/ajprenal.00212.2013.
Hall G, Rowell J, Farinelli F, Gbadegesin RA, Lavin P, Wu G, et al. Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. Am J Physiol Renal Physiol. 2014 Jun 15;306(12):F1442–50.
Hall, Gentzon, et al. “Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.Am J Physiol Renal Physiol, vol. 306, no. 12, June 2014, pp. F1442–50. Pubmed, doi:10.1152/ajprenal.00212.2013.
Hall G, Rowell J, Farinelli F, Gbadegesin RA, Lavin P, Wu G, Homstad A, Malone A, Lindsey T, Jiang R, Spurney R, Tomaselli GF, Kass DA, Winn MP. Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. Am J Physiol Renal Physiol. 2014 Jun 15;306(12):F1442–F1450.

Published In

Am J Physiol Renal Physiol

DOI

EISSN

1522-1466

Publication Date

June 15, 2014

Volume

306

Issue

12

Start / End Page

F1442 / F1450

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • TRPC6 Cation Channel
  • TRPC Cation Channels
  • Signal Transduction
  • Podocytes
  • Phosphorylation
  • Phosphoric Monoester Hydrolases
  • Phosphodiesterase 5 Inhibitors
  • NFATC Transcription Factors
  • Models, Animal